Bharat Parenterals Q2 FY27 Call: Key Dates, Metrics

Bharat Parenterals Ltd has scheduled its Q2 FY27 earnings conference call for October 30, 2026, at 4:00 PM IST. The call will cover the company’s operating and financial performance for the quarter and half-year ended September 30, 2026. The update follows a weak first quarter, when consolidated revenue declined year-on-year and the company reported a consolidated net loss. Investors will be watching the discussion for information on volumes, margins, exports and progress in the Innoxel business.

Q2 FY27 earnings call is scheduled for October 30

The company said shareholders can attend the conference call to hear management discuss quarterly results and performance. The scheduled call comes after Bharat Parenterals announced the closure of its trading window from October 1, 2026. The window will remain closed until 48 hours after the release of unaudited results for the quarter and half-year ended September 30, 2026. Such closures are part of the company’s stated process ahead of the publication of price-sensitive financial information.

First-quarter revenue declined 19.2% year-on-year

In Q1 FY27, Bharat Parenterals reported consolidated revenue of ₹93.7 crore, compared with ₹116.0 crore in Q1 FY26. This represented a year-on-year decline of 19.2%. EBITDA was ₹8.5 crore, down 38.0% from ₹13.8 crore a year earlier. The EBITDA margin declined to 9.1% from 11.9% in Q1 FY26, indicating that the revenue fall was accompanied by weaker operating profitability.

Consolidated loss widened in Q1 FY27

The company reported a consolidated net loss of ₹3.6 crore in Q1 FY27, compared with a loss of ₹0.9 crore in Q1 FY26. The net loss margin was 3.8%, versus 0.8% in the corresponding prior-year quarter. Separately, a reported result for the quarter ended June 2026 placed net profit at ₹1.01 crore, down 87.73% from ₹8.23 crore in the previous-year period. The supplied disclosures contain both consolidated and other reported figures, so investors should use the company’s published results to distinguish the relevant reporting basis.

Earlier production disruption affected Q2 FY26 revenue

Bharat Parenterals had reported a difficult Q2 FY26, with standalone revenue falling to ₹41.7 crore. The company attributed the decline to a planned production break for upgrades, temporary softness in institutional offtake and deferred export dispatches. These factors reduced volumes during the period. However, the company said the product mix shifted toward higher-value products, supporting an improvement in gross margins despite the lower revenue base.

Gross margin improvement reflected product mix

Standalone gross margin in Q2 FY26 was 44.1%, while consolidated gross margin was 58.3%. The figures show that profitability at the gross level improved even as production and dispatch factors affected sales. Margin movement is likely to remain an important point for the Q2 FY27 discussion, particularly after the Q1 FY27 EBITDA margin declined to 9.1%. The upcoming call may clarify whether production normalisation, institutional demand and export dispatches have changed during the September quarter.

Management has issued FY27 growth targets

Based on the Q1 FY27 investor presentation, Bharat Parenterals guided for standalone revenue growth of 10% to 15% year-on-year for FY27. Innoxel was targeted to deliver revenue growth of 35% to 45% year-on-year. The company also indicated that commercial CMO supply from Innoxel would begin in Q2 FY27. These targets set a measurable backdrop for the October earnings call, although the available material does not provide a Q2 FY27 financial outcome.

Commissioning timeline extends to September 2027

Management’s broader guidance included a commissioning target of September 2027 for a project referenced in the supplied information. First commercial supply is targeted in Q4 FY29. The timeline points to a phased capacity and commercialisation plan rather than an immediate contribution to FY27 revenue. Management also described its FY27 outlook as cautious but confident across segments, with emphasis on operational leverage and pipeline progression.

Annual report showed different standalone and consolidated outcomes

Bharat Parenterals filed its FY2025-26 annual report with BSE, reporting a consolidated loss of ₹27.31 crore. At the standalone level, it reported net profit of ₹16.02 crore. The company recommended a dividend of ₹1 per share. The difference between standalone and consolidated outcomes makes segment-level performance and subsidiary execution relevant for investors assessing the group’s financial position.

Key reported figures

What investors can track in the September-quarter update

The Q2 FY27 results and October 30 call will provide the next formal update on whether the company’s FY27 growth guidance is progressing. Relevant issues include the pace of standalone growth, Innoxel’s commercial CMO supply, margin movement and the status of export and institutional demand. The company has not published an earnings-call transcript for Q1 FY27, and the cited first-quarter figures were drawn from its investor presentation. Investors will therefore have a new opportunity to assess management commentary when Q2 FY27 results are released and discussed.

Conclusion

Bharat Parenterals enters its Q2 FY27 earnings update after lower Q1 revenue, weaker EBITDA and a wider consolidated loss. Its stated FY27 growth targets, Innoxel commercial supply plans and the September 2027 commissioning target will be central areas to track when management speaks on October 30, 2026.